

Drug Treatments / Multiple Sclerosis

Reference Number: RDF1196-23

Date of Response: 30/01/2023

Further to your Freedom of Information Act request, please find the Trust's response(s) below:

How many patients has your trust/health board treated in the past 6 months (for any disease) with the following drugs :

Drug	Eastern Service	Northern Service
Aubagio (teriflunomide)	43	0
Avonex (interferon beta-1a)	21	0
Betaferon (interferon beta-1b)	* <5	0
Brabio (glatiramer acetate)	0	0
Copaxone (glatiramer acetate)	28	5
Extavia (beta interferon-1b)	0	0
Gilenya (fingolimod)	18	0
Lemtrada (alemtuzumab)	* <5	0
Kesimpta (ofatumumab)	16	* <5
Mavenclad (cladribine)	12	0
Mayzent (siponimod)	6	0
Ocrevus (ocrelizumab)	27	0
Plegridy (peginterferon beta-1a)	11	9
Ponvory (ponesimod)	* <5	0
Rebif (beta interferon-1a)	0	* <5
Tecfidera (dimethyl fumarate)	110	16
Tysabri (natalizumab)	36	16
Tysabri (natalizumab) pre-filled syringes ONLY	28	10
Vumerity (diroximel fumarate)	0	0
Zeposia (ozanimod)	0	0

* - 5 - low number suppressed to protect patient identity

In accordance with section 40 (2) of the Freedom of Information Act 2000, we are unable to provide figures where the number of patients is less than or equal to five and could risk the identification of those patients and breach Caldicott principles.

It would also be very helpful if you could advise how many hospital patients (inpatients or outpatients) currently have a diagnosis for the following conditions:

Eastern Service response:-

- **Multiple sclerosis (any type)** - 901 patients
- **Relapsing remitting multiple sclerosis (RRMS)** - 557 patients
- **Primary progressive multiple sclerosis (PPMS)** - 111 patients
- **Secondary progressive multiple sclerosis (SPMS)** - 218 patients

Northern Service response:-

- **Primary Progressive** – 83
- **Secondary Progressive** 135
- **Progressive – not known** 15
- **Relapsing Remitting** 191
- **Not Known** <5
- **CIS** 11

* - 5 - low number suppressed to protect patient identity